108 related articles for article (PubMed ID: 27300431)
21. Strategies for targeting the androgen receptor axis in prostate cancer.
Carver BS
Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
[TBL] [Abstract][Full Text] [Related]
22. Reconsideration of progression to CRPC during androgen deprivation therapy.
Mizokami A; Namiki M
J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975
[TBL] [Abstract][Full Text] [Related]
23. Toppling the HAT to Treat Lethal Prostate Cancer.
Rasool RU; Natesan R; Asangani IA
Cancer Discov; 2021 May; 11(5):1011-1013. PubMed ID: 33947717
[TBL] [Abstract][Full Text] [Related]
24. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
25. Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy.
Shah K; Bradbury NA
Oncotarget; 2015 Jun; 6(16):14233-46. PubMed ID: 26008968
[TBL] [Abstract][Full Text] [Related]
26. AR-V7 Protein in Circulating Tumor Cells-The Decider for Therapy?
Montgomery RB; Plymate SR
JAMA Oncol; 2016 Nov; 2(11):1450-1451. PubMed ID: 27261766
[No Abstract] [Full Text] [Related]
27. Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer.
Bartek J; Mistrik M; Bartkova J
Cancer Discov; 2013 Nov; 3(11):1222-4. PubMed ID: 24203954
[TBL] [Abstract][Full Text] [Related]
28. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Bastos DA; Dzik C; Rathkopf D; Scher HI
Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.
Martinez-Ariza G; Hulme C
Pharm Pat Anal; 2015; 4(5):387-402. PubMed ID: 26389532
[TBL] [Abstract][Full Text] [Related]
31. Transcriptional network of androgen receptor in prostate cancer progression.
Takayama K; Inoue S
Int J Urol; 2013 Aug; 20(8):756-68. PubMed ID: 23600948
[TBL] [Abstract][Full Text] [Related]
32. Targeting androgen-independent pathways: new chances for patients with prostate cancer?
Cattrini C; Zanardi E; Vallome G; Cavo A; Cerbone L; Di Meglio A; Fabbroni C; Latocca MM; Rizzo F; Messina C; Rubagotti A; Barboro P; Boccardo F
Crit Rev Oncol Hematol; 2017 Oct; 118():42-53. PubMed ID: 28917268
[TBL] [Abstract][Full Text] [Related]
33. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.
Ferrari N; Granata I; Capaia M; Piccirillo M; Guarracino MR; Venè R; Brizzolara A; Petretto A; Inglese E; Morini M; Astigiano S; Amaro AA; Boccardo F; Balbi C; Barboro P
Cell Commun Signal; 2017 Dec; 15(1):51. PubMed ID: 29216878
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
35. [Molecular biology of castration-resistant prostate cancer].
Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
[TBL] [Abstract][Full Text] [Related]
36. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.
Bishop JL; Davies A; Ketola K; Zoubeidi A
Endocr Relat Cancer; 2015 Jun; 22(3):R165-82. PubMed ID: 25934687
[TBL] [Abstract][Full Text] [Related]
37. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.
Jin L; Garcia J; Chan E; de la Cruz C; Segal E; Merchant M; Kharbanda S; Raisner R; Haverty PM; Modrusan Z; Ly J; Choo E; Kaufman S; Beresini MH; Romero FA; Magnuson S; Gascoigne KE
Cancer Res; 2017 Oct; 77(20):5564-5575. PubMed ID: 28819026
[TBL] [Abstract][Full Text] [Related]
39. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
40. Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776-87.
Heidegger I; Pichler R; Pircher A
Eur Urol; 2017 Oct; 72(4):e102-e103. PubMed ID: 28602201
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
